Searchable abstracts of presentations at key conferences in endocrinology

ea0022p445 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

The use of receptor tyrosine kinase inhibitors in metastatic differentiated thyroid carcinoma

Gkountouvas Anastasios , Kostoglou-Athanassiou Ifigenia , Veniou Eirini , Thomas Dimitrios , Aggelopoulou Anastasia , Nikas Marios , Ziras Nicolaos , Kaldrymides Philippos

The management of metastatic differentiated thyroid carcinoma included until recently the use of therapeutic 131I, radiotherapy and in specific cases chemotherapy. However, recently new agents entered in the management of differentiated metastatic thyroid carcinoma which aim at specific cell receptors and inhibit the growth of the carcinoma in a specific and targeted way.The aim was to present the experience of the use of the receptor tyrosine...